N/A N=34 Unrelated Umbilical Cord Blood (UBC)Transplantation
Chronic Myelogenous Leukemia (CML) · Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome
Primary: Number of Participants With Engraftment — 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Targeting Burdensomeness Among Clinic Referred Youth
Perceived Burdensomeness Toward Others
Primary: 6-item Youth Perceived Burdensomeness Subscale of the Interpersonal Needs Questionnaire — 9.0 score on a scale
Phase 2 N=175 The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment
Infertility
Primary: Percentage of Oocyte Maturation — 49; 36; 76; 103 percentage of expected oocyte yield — p=<0.05
Phase 4 N=26 Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Metastatic Renal Cell Carcinoma · Metastatic Melanoma
Primary: Change in the Area Under the Concentration-Time Curve (AUC) From 0 to 8 Hours (AUC0-8) of Aldesleukin After One Cycle of Therapy — 60359.9; 173127.7; -22171.6 hour times…
Phase 3 N=91 Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
Thoracic Diseases · Postoperative Pain · Opioid Use
Primary: Average Daily In-Hospital Use of Opioids — 40; 45 Oral Morphine Equivalent per Day
Phase 2 N=263 Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
Chikungunya Virus Infection
Primary: Functional Anti-chikungunya Antibody Titers on Day 56 (28 Days Post Immunisation) Confirmed by Plaque Reduction Neutralization Test (PRNT50) — 50.2; 5.0; 12.9; 5.0 Titer…
Phase 2 N=3 Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
Primary: Phase 1: Dose Limiting Toxicities (DLT) Following Intravesical Administration of ABI-009 — 0; 0; 0; 0 Participants
N/A N=78 A Trial of Yoga in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Pediatric Quality of Life Inventory — 2.14; 1.5; 2.8 score on a scale
N/A N=25 Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.
Breast Cancer · Breast Cyst
Primary: Number of Serious Adverse Events, Directly Related to Normal Functioning of the Device — 0; 0; 0 Serious Adverse Events
Phase 2 N=6 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Phase 2 N=133 Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
Diarrhea-predominant Irritable Bowel Syndrome
Primary: 24-hour Worst Abdominal Pain Scores (WAP) at Day 29 Compared to Baseline (Averaged Over the Week Prior to Each Respective Time Point) — -1.64; -2.30; -2.00; -1.69 Score…
N/A N=383 Cognitive Remediation to Improve Mobility in Sedentary Seniors
Mobility Limitation · Motor Activity · Difficulty Walking
Primary: Change in Walking Speed During Single and Dual-task Conditions. — 1.73; 2.76; 6.02; 5.43 centimeters per second
N/A N=30 Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients
Pulmonary Disease, Chronic Obstructive · Hypercapnia · Hypoxia
Primary: Use of Oxygen Therapy by HNHF-O2 at Home — 6.8 Hours
Phase 3 N=422 The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Sepsis · Delirium · Impaired Cognition
Primary: Delirium/Coma Free Days (DCFDs) — 8; 7.5 days
Phase 2 N=25 Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
Multiple Myeloma
Primary: Beta-adrenergically Mediated Gene Expression (Change From Baseline) — -0.407; 0.0099 Unitless — p=.017